Login to Your Account

Sanofi Seeks to Beef Up Cancer Line with BiPar

By Donna Young

Thursday, April 16, 2009
Paris-based Sanofi-Aventis Group is buying cancer drugmaker BiPar Sciences Inc. in a deal potentially worth $500 million for the Brisbane, Calif.-based firm and its investors. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription